Keywords
Last Name

Harrison W. Farber, MD

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionPulmonary, Allergy, Sleep & Critical Care Medicine
Address72 E. Concord St Housman (R)
Boston MA 02118
Phone(617) 638-4860
ORCID ORCID Icon0000-0002-0297-7902
 Awards and Honors

Start-EndDescription
2010Robert Dawson Evans Special Recognition Teaching Award, Boston University School of Medicine
 Research Expertise & Professional Interests
Dr. Farber is considered an opinion leader and internationally recognized expert in the field of pulmonary hypertension. He is a Professor in the Department of Medicine and attends in the Medical Intensive Care Unit and on the Pulmonary Consultation Service at Boston Medical Center. He also oversees the care of all patients with Pulmonary Hypertension at Boston Medical Center.

Dr. Farber’s research focuses on endothelial cell biology, in particular, the response of the pulmonary vasculature to injury. He has extensive government and private funding and is an NIH-funded Principle Investigator on several grants. He is a member of several research groups both within the Pulmonary Center and in other divisions within the Department of Medicine: the Pulmonary Vascular Biology Group (Pulmonary Center); the Center for Excellence in Sickle Cell Disease (Hematology), the Scleroderma Vascular Disease Group (Rheumatology) and Pulmonary Vascular/Left Ventricular Study Group (Cardiology). Dr. Farber’s laboratory is investigating the response of the pulmonary vasculature in different etiologies of pulmonary hypertension using genomic and proteomic approaches to identify unique molecules as potential targets for new therapies for pulmonary hypertension associated with sickle cell disease, with scleroderma, and with left ventricular diastolic dysfunction.

Dr. Farber's team is developing a database and registry of sickle cell patients with pulmonary hypertension (see Dr. Elizabeth Klings' faculty profile) as well as a database and registry of scleroderma patients with various forms of pulmonary disease including pulmonary hypertension. They are participating in numerous multi-center clinical trials of new therapies for pulmonary hypertension and have several single-site trials for novel proof of concept therapies for pulmonary hypertension.

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 2017 Mar 23; 9(1):27. PMID: 28330499.
    View in: PubMed
  2. Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev. 2016 Dec; 25(142):418-430. PMID: 27903664.
    View in: PubMed
  3. Sardana M, Moll M, Farber HW. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2016 Dec; 12(12):1513-1520. PMID: 27756196.
    View in: PubMed
  4. Preston IR, Farber HW. Anti-coagulation in pulmonary arterial hypertension: the real blood and guts. J Thorac Dis. 2016 Sep; 8(9):E1106-E1107. PMID: 27747077.
    View in: PubMed
  5. Finch KT, Stratton EA, Farber HW. Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. J Heart Lung Transplant. 2016 Nov; 35(11):1370-1373. PMID: 27623099.
    View in: PubMed
  6. Cheong FY, Gower AC, Farber HW. Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Semin Arthritis Rheum. 2017 Feb; 46(4):465-472. PMID: 27499522.
    View in: PubMed
  7. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW. Response to Letter Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)". Circulation. 2016 May 17; 133(20):e662. PMID: 27185031.
    View in: PubMed
  8. Lenna S, Assassi S, Farina GA, Mantero JC, Scorza R, Lafyatis R, Farber HW, Trojanowska M. The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients. Arthritis Res Ther. 2015; 17:363. PMID: 26669670.
    View in: PubMed
  9. Moll M, Payne JG, Tukey MH, Farber HW. Gestational pulmonary arterial hypertension. Pulm Circ. 2015 Dec; 5(4):730-3. PMID: 26697182.
    View in: PubMed
  10. Waxman AB, Farber HW. Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. Circulation. 2015 Dec 1; 132(22):2152-61. PMID: 26621638.
    View in: PubMed
  11. Farber HW, Gibbs S. Under pressure: pulmonary hypertension associated with left heart disease. Eur Respir Rev. 2015 Dec; 24(138):665-73. PMID: 26621980.
    View in: PubMed
  12. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015 Dec 22; 132(25):2403-11. PMID: 26510696.
    View in: PubMed
  13. Sardana M, Moll M, Farber HW. Novel investigational therapies for treating pulmonary arterial hypertension. Expert Opin Investig Drugs. 2015; 24(12):1571-96. PMID: 26484967.
    View in: PubMed
  14. Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015 Nov; 90(11):1060-4. PMID: 26284693.
    View in: PubMed
  15. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015 Oct; 148(4):1043-54. PMID: 26066077.
    View in: PubMed
  16. Henriques-Forsythe M, Annangi S, Farber HW. Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States. Pulm Circ. 2015 Sep; 5(3):506-12. PMID: 26401251.
    View in: PubMed
  17. Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I. Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc. 2015 Jun; 12(6):960. PMID: 26075562.
    View in: PubMed
  18. Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015 Jul; 46(1):152-64. PMID: 25837032.
    View in: PubMed
  19. Grossman NL, Fiack CA, Weinberg JM, Rybin DV, Farber HW. Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost. Pulm Circ. 2015 Mar; 5(1):198-203. PMID: 25992282.
    View in: PubMed
  20. Verla T, Marky A, Farber H, Petraglia FW, Gallis J, Lokhnygina Y, Parente B, Hickey P, Turner DA, Lad SP. Impact of advancing age on post-operative complications of deep brain stimulation surgery for essential tremor. J Clin Neurosci. 2015 May; 22(5):872-6. PMID: 25669119.
    View in: PubMed
  21. Frantz RP, Schilz RJ, Chakinala MM, Badesch DB, Frost AE, McLaughlin VV, Barst RJ, Rosenberg DM, Miller DP, Hartline BK, Benton WW, Farber HW. Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. Chest. 2015 Feb; 147(2):484-94. PMID: 25320967.
    View in: PubMed
  22. Hill NS, Badesch D, Benza RL, D'Eletto TA, Farber HW, Gomberg-Maitland M, Hassoun PM, Preston I. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc. 2015 Feb; 12(2):269-73. PMID: 25590376.
    View in: PubMed
  23. Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, McGoon M, Nicolls MR, Zamanian RT. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014 Dec; 146(6):1494-504. PMID: 24992469.
    View in: PubMed
  24. Bradford MA, Farber HW. Are we correctly defining intermediate-risk pulmonary embolism? Chest. 2014 Nov; 146(5):e169. PMID: 25367487.
    View in: PubMed
  25. Hellawell JL, Bhattacharya S, Farber HW. Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2014 Oct; 10(10):1445-53. PMID: 25204984.
    View in: PubMed
  26. Gopal DM, Doldt B, Finch K, Simms RW, Farber HW, Gokce N. Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken). 2014 Sep; 66(9):1386-94. PMID: 24515598.
    View in: PubMed
  27. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015 Mar; 34(3):362-8. PMID: 25312386.
    View in: PubMed
  28. Farber HW, Miller DP. Cause of death in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 Feb; 33(2):222. PMID: 24365766.
    View in: PubMed
  29. Machado RF, Farber HW. Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. Clin Chest Med. 2013 Dec; 34(4):739-52. PMID: 24267302.
    View in: PubMed
  30. Miller DP, Farber HW. "Who'll be the next in line?" The lung allocation score in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2013 Dec; 32(12):1165-7. PMID: 24210050.
    View in: PubMed
  31. Farber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant. 2013 Nov; 32(11):1114-22. PMID: 24035189.
    View in: PubMed
  32. Sadoughi A, Roberts KE, Preston IR, Lai GP, McCollister DH, Farber HW, Hill NS. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest. 2013 Aug; 144(2):531-41. PMID: 23558791.
    View in: PubMed
  33. Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013 Jul; 144(1):169-76. PMID: 23348820.
    View in: PubMed
  34. Lenna S, Farina AG, Martyanov V, Christmann RB, Wood TA, Farber HW, Scorza R, Whitfield ML, Lafyatis R, Trojanowska M. Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. Arthritis Rheum. 2013 May; 65(5):1357-66. PMID: 23400395.
    View in: PubMed
  35. Esch JJ, Shah PB, Cockrill BA, Farber HW, Landzberg MJ, Mehra MR, Mullen MP, Opotowsky AR, Waxman AB, Lock JE, Marshall AC. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant. 2013 Apr; 32(4):381-7. PMID: 23415728.
    View in: PubMed
  36. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013 Jan; 143(1):185-95. PMID: 22661451.
    View in: PubMed
  37. Skondra D, Chang GC, Farber HW, Eliott D. Ophthalmologic diagnosis of exacerbation of idiopathic pulmonary arterial hypertension. Arch Ophthalmol. 2012 Dec; 130(12):1619-21. PMID: 23229713.
    View in: PubMed
  38. Kitterman N, Poms A, Miller DP, Lombardi S, Farber HW, Barst RJ. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Mayo Clin Proc. 2012 Sep; 87(9):825-34. PMID: 22883740.
    View in: PubMed
  39. Farber HW. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Circulation. 2012 Jul 17; 126(3):258-60. PMID: 22696078.
    View in: PubMed
  40. Farber HW. Pulmonary arterial hypertension in patients with HIV infection. European Respiratory Monograph. 2012; 57:82-93.
  41. Schilz R, Farber HW. Quality initiatives and models of care in patients with pulmonary arterial hypertension: the time has come! Int J Clin Pract Suppl. 2011 Dec; (174):1-3. PMID: 22171815.
    View in: PubMed
  42. York M, Farber HW. Pulmonary hypertension: screening and evaluation in scleroderma. Curr Opin Rheumatol. 2011 Nov; 23(6):536-44. PMID: 21934501.
    View in: PubMed
  43. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9. PMID: 21884013.
    View in: PubMed
  44. Christmann RB, Hayes E, Pendergrass S, Padilla C, Farina G, Affandi AJ, Whitfield ML, Farber HW, Lafyatis R. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum. 2011 Jun; 63(6):1718-28. PMID: 21425123.
    View in: PubMed
  45. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest. 2011 Jul; 140(1):19-26. PMID: 21393391.
    View in: PubMed
  46. Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail. 2011 Mar-Apr; 17(2):56-64. PMID: 21449993.
    View in: PubMed
  47. Walkey AJ, Fein D, Horbowicz KJ, Farber HW. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther. 2011 Aug; 24(4):421-5. PMID: 21251994.
    View in: PubMed
  48. Lazar HL, Farber HW. Acute pulmonary embolism. N Engl J Med. 2010 Nov 11; 363(20):1974; author reply 1974-5. PMID: 21067400.
    View in: PubMed
  49. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, Lafyatis R. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One. 2010; 5(8):e12106. PMID: 20808962.
    View in: PubMed
  50. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37. PMID: 20558556.
    View in: PubMed
  51. Walkey AJ, Ieong M, Alikhan M, Farber HW. Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis. J Rheumatol. 2010 Sep; 37(9):1871-7. PMID: 20551099.
    View in: PubMed
  52. Farber HW, Simms RW, Lafyatis R. Care of patients with scleroderma in the intensive care setting. J Intensive Care Med. 2010 Sep; 25(5):247-58. PMID: 20542965.
    View in: PubMed
  53. Farber HW, Walkey AJ, O'Donnell MR. Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Jul; 29(7):825-6. PMID: 20456982.
    View in: PubMed
  54. Hardy H, Backman ES, Farber HW. Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. Pharmacotherapy. 2010 Apr; 30(4):139e-44e. PMID: 20334465.
    View in: PubMed
  55. Lazar HL, Farber HW. Early pulmonary embolectomy for acute pulmonary embolus: an operation whose time has come. J Card Surg. 2010 May; 25(3):259-60. PMID: 20202028.
    View in: PubMed
  56. Farber HW, Walkey AJ, Alikhan MM. The role of aldosterone in pulmonary venous hypertension. Chest. 2010 Feb; 137(2):502; author reply 502. PMID: 20133311.
    View in: PubMed
  57. Fiack CA, Farber HW. Pulmonary hypertension associated with left ventricular diastolic dysfunction. J Heart Lung Transplant. 2010 Feb; 29(2):230-1. PMID: 20113913.
    View in: PubMed
  58. Walkey AJ, Farber HW, O'Donnell C, Cabral H, Eagan JS, Philippides GJ. The accuracy of the central venous blood gas for acid-base monitoring. J Intensive Care Med. 2010 Mar-Apr; 25(2):104-10. PMID: 20018607.
    View in: PubMed
  59. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87. PMID: 19837821.
    View in: PubMed
  60. Summer R, Fiack CA, Ikeda Y, Sato K, Dwyer D, Ouchi N, Fine A, Farber HW, Walsh K. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol. 2009 Sep; 297(3):L432-8. PMID: 19561137.
    View in: PubMed
  61. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619. PMID: 19389575.
    View in: PubMed
  62. Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr; 157(4):625-35. PMID: 19332188.
    View in: PubMed
  63. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94. PMID: 19332472.
    View in: PubMed
  64. Safaya S, Klings ES, Odhiambo A, Li G, Farber HW, Steinberg MH. Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: differential expression patterns in pulmonary artery and microvascular endothelial cells. Cytokine. 2009 Apr; 46(1):72-8. PMID: 19251437.
    View in: PubMed
  65. Petcu, EB, Berman L, Opris MM, Gheorghiu V, Kessler SC, Hayes J, Farber HW. Pulmonary hypertension in systemic lupus erythematosus complicated by exposure to dexfenfluramine. Rom J Leg Med. 2009; 17:83-88.
  66. Wilson KC, Farber HW. Propylene glycol accumulation during continuous-infusion lorazepam in critically ill patients. J Intensive Care Med. 2008 Nov-Dec; 23(6):413; author reply 414-5. PMID: 19019841.
    View in: PubMed
  67. McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug; 83(8):923-31. PMID: 18674477.
    View in: PubMed
  68. Klings ES, Anton Bland D, Rosenman D, Princeton S, Odhiambo A, Li G, Bernard SA, Steinberg MH, Farber HW. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol. 2008 Jul; 83(7):547-53. PMID: 18383329.
    View in: PubMed
  69. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum. 2008 Jun 15; 59(6):867-75. PMID: 18512721.
    View in: PubMed
  70. Farber HW. The status of pulmonary arterial hypertension in 2008. Circulation. 2008 Jun 10; 117(23):2966-8. PMID: 18541751.
    View in: PubMed
  71. Gaposchkin DP, Farber HW, Zoeller RA. On the importance of plasmalogen status in stimulated arachidonic acid release in the macrophage cell line RAW 264.7. Biochim Biophys Acta. 2008 Apr; 1781(4):213-9. PMID: 18328831.
    View in: PubMed
  72. Fisher KA, Hill NS, Farber HW. Pathophysiology of Pulmonary Arterial Hypertension. In Pulmonary Hypertension (NS Hill & HW Farber, eds). Humana Press. Totowa, NJ. 2008; 145-172.
  73. Farber HW. Pathophysiology of Pulmonary Arterial Hypertension. In Pulmonary Hypertension (NS Hill & HW Farber, eds). Humana Press. Totowa, NJ. 2008; 51-72.
  74. Miller NS, Dobre MC, Liebschutz JM, Williams TC, Orr BL, Farber HW. Clinical Microbiology Newsletter. Micrococcus Bacteremia in a Patient with Pulmonary Hypertension and a Long-term Central Venous Catheter: Opportunity Knocks, and an Unexpected Pathogen Enters. 2007; 29(22):173-175.
  75. Odhiambo A, Perlman DH, Huang H, Costello CE, Farber HW, Steinberg MH, McComb ME, Klings ES. Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. Rapid Commun Mass Spectrom. 2007; 21(14):2195-203. PMID: 17569101.
    View in: PubMed
  76. Steiner MK, Preston IR, Klinger JR, Criner GJ, Waxman AB, Farber HW, Hill NS. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest. 2006 Nov; 130(5):1471-80. PMID: 17099026.
    View in: PubMed
  77. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006 Nov; 130(5):1481-8. PMID: 17099027.
    View in: PubMed
  78. Fiack CA, Farber HW. Heart failure with preserved ejection fraction. N Engl J Med. 2006 Oct 26; 355(17):1828; author reply 1830-1. PMID: 17065647.
    View in: PubMed
  79. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med. 2006 Jul 18; 145(2):152-3. PMID: 16847299.
    View in: PubMed
  80. Tam DH, Farber HW. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. Am J Hematol. 2006 Jun; 81(6):443-7. PMID: 16680745.
    View in: PubMed
  81. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest. 2006 Feb; 129(2):417-25. PMID: 16478861.
    View in: PubMed
  82. Ieong MH, Farber HW. Non-infectious pulmonary complications of HIV infection. Clin Pulm Med. 2006; 13:194-202.
  83. Zheng H, Duclos RI, Smith CC, Farber HW, Zoeller RA. Synthesis and biological properties of the fluorescent ether lipid precursor 1-O-[9'-(1'-pyrenyl)]nonyl-sn-glycerol. J Lipid Res. 2006 Mar; 47(3):633-42. PMID: 16369049.
    View in: PubMed
  84. Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med. 2005 Dec; 99(12):1501-10. PMID: 15890512.
    View in: PubMed
  85. Klinger JR, Houtchens J, Thaker S, Hill NS, Farber H. Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. Chest. 2005 Dec; 128(6 Suppl):618S-619S. PMID: 16373873.
    View in: PubMed
  86. Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest. 2005 Sep; 128(3):1674-81. PMID: 16162774.
    View in: PubMed
  87. Klings ES, Safaya S, Adewoye AH, Odhiambo A, Frampton G, Lenburg M, Gerry N, Sebastiani P, Steinberg MH, Farber HW. Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. Physiol Genomics. 2005 May 11; 21(3):293-8. PMID: 15741505.
    View in: PubMed
  88. Adewoye AH, Klings ES, Farber HW, Palaima E, Bausero MA, McMahon L, Odhiambo A, Surinder S, Yoder M, Steinberg MH, Asea A. Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70. Am J Hematol. 2005 Mar; 78(3):240-2. PMID: 15726596.
    View in: PubMed
  89. Farber HW, Loscalzo J. Mechanism of disease: Pulmonary hypertension. Discov Med. 2005 Feb; 5(25):80-7. PMID: 20704929.
    View in: PubMed
  90. Steinberg MH, Farber HW. Sickle Cell Disease. In Hospital Medicine (RM Wachter, L Goldman & H Hollander, eds). Lippincott Williams & Wilkins. Philadelphia. 2005; 965-974.
  91. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004 Oct 14; 351(16):1655-65. PMID: 15483284.
    View in: PubMed
  92. Klings ES, Farber HW. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004 Jun 10; 350(24):2521-2; author reply 2521-2. PMID: 15190149.
    View in: PubMed
  93. Wilson KC, Bielska B, Farber HW. Mycobacterium marinum osteomyelitis. Orthopedics. 2003 Mar; 26(3):331-2. PMID: 12650330.
    View in: PubMed
  94. Farber HW. Pulmonary Hypertension. In the Merck Manual (M.H. Beers, ed). 2003; 322-325.
  95. Klings ES, Farber HW. The Pathogenesis of HIV-associated Pulmonary Hypertension. In HIV infection and the Cardiovascular System (G. Barbaro, editor). Karger. Basel. 2003; 71-82.
  96. Klings ES, Farber HW. The pathogenesis of HIV-associated pulmonary hypertension. Adv Cardiol. 2003; 40:71-82. PMID: 14533547.
    View in: PubMed
  97. Burkart, K, Farber HW. HIV-associated Pulmonary Hypertension: Diagnosis and Treatment. In HIV infection and the Cardiovascular System (G. Barbaro, editor). Karger. Basel. 2003; 197-207.
  98. Burkart KM, Farber HW. HIV-associated pulmonary hypertension: diagnosis and treatment. Adv Cardiol. 2003; 40:197-207. PMID: 14533555.
    View in: PubMed
  99. Zoeller RA, Grazia TJ, LaCamera P, Park J, Gaposchkin DP, Farber HW. Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am J Physiol Heart Circ Physiol. 2002 Aug; 283(2):H671-9. PMID: 12124215.
    View in: PubMed
  100. Jones H, Aguila E, Farber HW. Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis. Ann Intern Med. 2002 Jul 2; 137(1):74. PMID: 12093261.
    View in: PubMed
  101. Graven KK, Molvar C, Roncarati JS, Klahn BD, Lowrey S, Farber HW. Identification of protein disulfide isomerase as an endothelial hypoxic stress protein. Am J Physiol Lung Cell Mol Physiol. 2002 May; 282(5):L996-1003. PMID: 11943664.
    View in: PubMed
  102. Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2002 Apr; 282(4):H1255-61. PMID: 11893559.
    View in: PubMed
  103. Hoeper MM, Galié N, Murali S, Olschewski H, Rubenfire M, Robbins IM, Farber HW, McLaughlin V, Shapiro S, Pepke-Zaba J, Winkler J, Ewert R, Opitz C, Westerkamp V, Vachiéry JL, Torbicki A, Behr J, Barst RJ. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002 Feb 1; 165(3):341-4. PMID: 11818318.
    View in: PubMed
  104. Wittram C, Fogg J, Farber H. Immune restoration syndrome manifested by pulmonary sarcoidosis. AJR Am J Roentgenol. 2001 Dec; 177(6):1427. PMID: 11717100.
    View in: PubMed
  105. Klings ES, Christman BW, McClung J, Stucchi AF, McMahon L, Brauer M, Farber HW. Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am J Respir Crit Care Med. 2001 Oct 1; 164(7):1248-52. PMID: 11673218.
    View in: PubMed
  106. Klings ES, Farber HW. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respir Res. 2001; 2(5):280-5. PMID: 11686897.
    View in: PubMed
  107. Healy AM, Schwartz JJ, Zhu X, Herrick BE, Varnum B, Farber HW. Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2001 Jun; 280(6):L1273-81. PMID: 11350808.
    View in: PubMed
  108. Farber HW. HIV-associated pulmonary hypertension. AIDS Clin Care. 2001 Jun; 13(6):53-5, 59. PMID: 11710309.
    View in: PubMed
  109. Strohmeier GR, Walsh JH, Klings ES, Farber HW, Cruikshank WW, Center DM, Fenton MJ. Lipopolysaccharide binding protein potentiates airway reactivity in a murine model of allergic asthma. J Immunol. 2001 Feb 1; 166(3):2063-70. PMID: 11160257.
    View in: PubMed
  110. Scarfo LM, Weller PF, Farber HW. Induction of endothelial cell cytoplasmic lipid bodies during hypoxia. Am J Physiol Heart Circ Physiol. 2001 Jan; 280(1):H294-301. PMID: 11123244.
    View in: PubMed
  111. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs. 2001; 61(13):1945-56. PMID: 11708765.
    View in: PubMed
  112. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000 Nov; 162(5):1846-50. PMID: 11069824.
    View in: PubMed
  113. Healy AM, Morgenthau L, Zhu X, Farber HW, Cardoso WV. VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. Dev Dyn. 2000 Nov; 219(3):341-52. PMID: 11066091.
    View in: PubMed
  114. Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. N Engl J Med. 2000 Sep 14; 343(11):815. PMID: 10991709.
    View in: PubMed
  115. Klings ES, Farber HW. IV epoprostenol for systemic sclerosis. Chest. 2000 Sep; 118(3):881-2. PMID: 10988225.
    View in: PubMed
  116. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000 Aug; 106(4):483-91. PMID: 10953023.
    View in: PubMed
  117. Klings ES, Farber HW. Epoprostenol for pulmonary hypertension in scleroderma. Ann Intern Med. 2000 Jul 18; 133(2):158. PMID: 10896643.
    View in: PubMed
  118. Hendra KP, Farber HW. Foreign body granulomatosis. In Internal Medicine Pearls (Heffner JE, Sahn SA, eds). Hanley & Belfus, Inc. Philadelphia. 2000; 228-230.
  119. Panchenko MV, Farber HW, Korn JH. Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol. 2000 Jan; 278(1):C92-C101. PMID: 10644516.
    View in: PubMed
  120. Farber HW, Loscalzo J. Prothrombotic mechanisms in primary pulmonary hypertension. J Lab Clin Med. 1999 Dec; 134(6):561-6. PMID: 10595782.
    View in: PubMed
  121. Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum. 1999 Dec; 42(12):2638-45. PMID: 10616012.
    View in: PubMed
  122. Graven KK, Yu Q, Pan D, Roncarati JS, Farber HW. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim Biophys Acta. 1999 Oct 28; 1447(2-3):208-18. PMID: 10542317.
    View in: PubMed
  123. Hammerman SI, Klings ES, Hendra KP, Upchurch GR, Rishikof DC, Loscalzo J, Farber HW. Endothelial cell nitric oxide production in acute chest syndrome. Am J Physiol. 1999 Oct; 277(4 Pt 2):H1579-92. PMID: 10516198.
    View in: PubMed
  124. Keaveny AP, Karasik MS, Farber HW. Successful treatment of chylous ascites secondary to Mycobacterium avium complex in a patient with the acquired immune deficiency syndrome. Am J Gastroenterol. 1999 Jun; 94(6):1689-90. PMID: 10364047.
    View in: PubMed
  125. Farber HW, Graven KK, Kokolski G, Korn JH. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol. 1999 May; 26(5):1195-6. PMID: 10332990.
    View in: PubMed
  126. Graven KK, Farber HW. Endothelial cell hypoxic stress proteins. J Lab Clin Med. 1998 Dec; 132(6):456-63. PMID: 9851734.
    View in: PubMed
  127. Farber HW, Graven KK. Endothelial cell hypoxic stress proteins. Chest. 1998 Jul; 114(1 Suppl):64S-65S. PMID: 9676633.
    View in: PubMed
  128. Tucci M, Nygard K, Tanswell BV, Farber HW, Hill DJ, Han VK. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. J Endocrinol. 1998 Apr; 157(1):13-24. PMID: 9614353.
    View in: PubMed
  129. Graven KK, McDonald RJ, Farber HW. Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase. Am J Physiol. 1998 Feb; 274(2 Pt 1):C347-55. PMID: 9486123.
    View in: PubMed
  130. Rounds S, Piggott D, Dawicki DD, Farber HW. Effect of hypercarbia on surface proteins of cultured bovine endothelial cells. Am J Physiol. 1997 Dec; 273(6 Pt 1):L1141-6. PMID: 9435568.
    View in: PubMed
  131. Hammerman SI, Kourembanas S, Conca TJ, Tucci M, Brauer M, Farber HW. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 1997 Jul; 156(1):280-5. PMID: 9230761.
    View in: PubMed
  132. Crimlisk JT, Bernardo J, Blansfield JS, Loughlin M, McGonagle EG, McEachern G, Roeber J, Farber HW. Endotracheal reintubation: a closer look at a preventable condition. Clin Nurse Spec. 1997 Jul; 11(4):145-50; quiz 151-2. PMID: 9274152.
    View in: PubMed
  133. Tucci M, Hammerman SI, Furfaro S, Saukonnen JJ, Conca TJ, Farber HW. Distinct effect of hypoxia on endothelial cell proliferation and cycling. Am J Physiol. 1997 May; 272(5 Pt 1):C1700-8. PMID: 9176162.
    View in: PubMed
  134. Graven KK, Farber HW. Endothelial hypoxic stress proteins. Kidney Int. 1997 Feb; 51(2):426-37. PMID: 9027717.
    View in: PubMed
  135. Saukkonen JJ, Farber HW. Lymphocytic Interstitial Pneumonitis. In AIDS and Respiratory Medicine (Zumla A, Johnson MA, Miller RF, eds.). Chapman & Hall. London. 1997; 331-343.
  136. Wagner RP, Farber HW. HIV-Related pulmonary problems. In A Practical Approach to Pulmonary Medicine (Goldstein RH, O'Connell JJ, Karlinsky JB, eds.). Lipincott-Raven. Philadelphia. 1997; 416-436.
  137. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, McInnis B, Nieves RL, Bernardo J. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med. 1996 Nov; 154(5):1473-7. PMID: 8912767.
    View in: PubMed
  138. Tucci M, McDonald RJ, Aaronson R, Graven KK, Farber HW. Specificity and uniqueness of endothelial cell stress responses. Am J Physiol. 1996 Sep; 271(3 Pt 1):L341-8. PMID: 8843781.
    View in: PubMed
  139. Wagner RP, Farber HW. Pulmonary manifestations. In HIV Infection: A Primary Care Manual (Libman H, Witzburg RA, eds.). Little, Brown and Co. Boston. 1996; 139-163..
  140. Farber HW, Barber TW. Mycobacterial infections. In HIV Infection: A Primary Care Manual (Libman H, Witzburg RA, eds.). Little, Brown and Co. Boston. 1996; 309-324.
  141. Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW. Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem. 1995 Nov 17; 270(46):27752-7. PMID: 7499243.
    View in: PubMed
  142. Graven KK, Farber HW. Hypoxia-associated proteins. New Horiz. 1995 May; 3(2):208-18. PMID: 7583162.
    View in: PubMed
  143. Farber HW. Long-term resolution of disseminated Mycobacterium avium complex infection in a patient with AIDS. Clin Infect Dis. 1995 Apr; 20(4):1067-8. PMID: 7795056.
    View in: PubMed
  144. Tretyakov AV, Farber HW. Endothelial cell tolerance to hypoxia. Potential role of purine nucleotide phosphates. J Clin Invest. 1995 Feb; 95(2):738-44. PMID: 7860755.
    View in: PubMed
  145. Montgomery AB, Feigal DW, Jr., Sattler F, Mason GR, Catanzaro A, Edison R, Markowitz N, Johnson E, Ogawa S, Rovzar M, Udem SA, Eden E, Hyslop N, Cheung TW, Kessler H, Mildvan D, Giron JA, Ettinger N, Crumpacker C, Frame, P, Steigbigel N, van der Horst C, Hirsch M, Lederman MM, Hewitt RG, Fallat R, Farber HW, Sacks HS, Eisman SA, Luce JM, Boylan T, Adams M, Feinberg J,Hopewell PC. Pentamidine aerosolized versus trimethoprim-sulfamethoxazole for pneumocystis carinii in Acquired Immunodeficiency Syndrome. Am J Respir Crit Care Med. 1995; 151:1068-1074.
  146. Crimlisk JT, Paris R, McGonagle EG, Calcutt JA, Farber HW. The closed tracheal suction system: implications for critical care nursing. Dimens Crit Care Nurs. 1994 Nov-Dec; 13(6):292-300. PMID: 7729318.
    View in: PubMed
  147. Lee VW, Cooley TP, Fuller JD, Ward RJ, Farber HW. Pulmonary mycobacterial infections in AIDS: characteristic pattern of thallium and gallium scan mismatch. Radiology. 1994 Nov; 193(2):389-92. PMID: 7972748.
    View in: PubMed
  148. Graven KK, Troxler RF, Kornfeld H, Panchenko MV, Farber HW. Regulation of endothelial cell glyceraldehyde-3-phosphate dehydrogenase expression by hypoxia. J Biol Chem. 1994 Sep 30; 269(39):24446-53. PMID: 7929107.
    View in: PubMed
  149. Katz MF, Farber HW, Dodds-Stitt Z, Cruikshank WW, Beer DJ. Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic and growth factor. J Leukoc Biol. 1994 May; 55(5):567-73. PMID: 7514199.
    View in: PubMed
  150. Katz MF, Beer DJ, Duquette D, Cruikshank WW, Antonov AS, Romanov YA, Smirnov VN, Farber HW. Secretion of a novel T-lymphocyte cytokine possessing both chemotactic and growth factor activity by serotonin-stimulated human aortic endothelial cells. Exp Cell Res. 1994 May; 212(1):113-9. PMID: 8174633.
    View in: PubMed
  151. Tarpy SP, Farber HW. Chronic lung disease: when to prescribe home oxygen. Geriatrics. 1994 Feb; 49(2):27-8, 31-3. PMID: 8307386.
    View in: PubMed
  152. Graven KK, Zimmerman LH, Dickson EW, Weinhouse GL, Farber HW. Endothelial cell hypoxia associated proteins are cell and stress specific. J Cell Physiol. 1993 Dec; 157(3):544-54. PMID: 8253866.
    View in: PubMed
  153. Weinhouse GL, Belloni PN, Farber HW. Effect of hypoxia on endothelial cell surface glycoprotein expression: modulation of glycoprotein IIIa and other specific surface glycoproteins. Exp Cell Res. 1993 Oct; 208(2):465-78. PMID: 8375475.
    View in: PubMed
  154. Tretyakov AV, Farber HW. Endothelial cell phospholipid distribution and phospholipase activity during acute and chronic hypoxia. Am J Physiol. 1993 Sep; 265(3 Pt 1):C770-80. PMID: 8214033.
    View in: PubMed
  155. Farber HW, Barber TW. Mycobacterial infections. In Clinical Manual of HIV Infection (Libman H, Witzburg RA, eds.). Little, Brown and Co. Boston. 1993; 263-274.
  156. Beer DJ, Farber HW. Secretion profiles of vasoactive amine-induced leukocyte chemoattractants: Evidence for endothelial cell heterogeneity. Signal Transduction in Lung Cells (Brody JS, Center DM, Tkachuck V, eds). Marcel Dekker, Inc. New York. 1993; 435-457.
  157. Wagner RP, Farber HW. Pulmonary manifestations. In Clinical Manual of HIV Infection (Libman H, Witzburg RA, eds.). Little, Brown and Co. Boston. 1993; 124-145.
  158. Karlinsky JB, Rounds S, Farber HW. Effects of hypoxia on heparan sulfate in bovine aortic and pulmonary artery endothelial cells. Circ Res. 1992 Oct; 71(4):782-9. PMID: 1516155.
    View in: PubMed
  159. Montecalvo MA, Steger KA, Farber HW, Smith BF, Dennis RC, Fitzpatrick GF, Pollack SD, Korsberg TZ, Birkett DH, Hirsch EF, et al. Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings. The Critical Care Research Team. Crit Care Med. 1992 Oct; 20(10):1377-87. PMID: 1395657.
    View in: PubMed
  160. Farber HW, Antonov AS, Romanov YA, Smirnov VN, Scarfo LM, Beer DJ. Cytokine secretion by human aortic endothelial cells is related to degree of atherosclerosis. Am J Physiol. 1992 Apr; 262(4 Pt 2):H1088-95. PMID: 1566891.
    View in: PubMed
  161. Simms RW, Zerbini CAF, Ferrante N, Anthony J, Felson DT, Craven DE and the Boston City Hospital Clinical AIDS Team (Chen J, Chapman SE, Cooley TP, Fuller JD, Libman H, Lebow J, Fagan M, Farber HW, Martin M, Steger KA, Zeeman BA). Fibromyalgia syndrome in patients infected with human immunodeficiency virus. Am J Med. 1992; 92:368-374.
  162. Farber HW, Kozlova M, Moldobalva A, Charles A, Danilov SM. Production of neutrophil-specific lipid chemoattractant activity by cultured endothelial cells: heterogeneity dependent on species, ligand, or endothelial cell site of origin. Tissue Cell. 1992; 24(3):355-66. PMID: 1636173.
    View in: PubMed
  163. Hill NS, Jacoby C, Farber HW. Effect of an endurance triathlon on pulmonary function. Med Sci Sports Exerc. 1991 Nov; 23(11):1260-4. PMID: 1766341.
    View in: PubMed
  164. Barber TW, Craven DE, Farber HW. Mycobacterium gordonae: a possible opportunistic respiratory tract pathogen in patients with advanced human immunodeficiency virus, type 1 infection. Chest. 1991 Sep; 100(3):716-20. PMID: 1889262.
    View in: PubMed
  165. Farber HW, Schaefer EJ, Franey R, Grimaldi R, Hill NS. The endurance triathlon: metabolic changes after each event and during recovery. Med Sci Sports Exerc. 1991 Aug; 23(8):959-65. PMID: 1956272.
    View in: PubMed
  166. Charles A, Rounds S, Farber HW. Neutrophil chemoattractant production by cultured serotonin-stimulated bovine and human endothelial cells. Am J Physiol. 1991 Aug; 261(2 Pt 1):L133-9. PMID: 1872407.
    View in: PubMed
  167. Farber HW, Beer DJ. Restricted secretion of a T-lymphocyte chemotactic cytokine by serotonin-stimulated cultured aortic endothelial cells. Circ Res. 1991 Aug; 69(2):257-65. PMID: 1860174.
    View in: PubMed
  168. Villanueva AG, Farber HW, Rounds S, Goldstein RH. Stimulation of fibroblast collagen and total protein formation by an endothelial cell-derived factor. Circ Res. 1991 Jul; 69(1):134-41. PMID: 2054930.
    View in: PubMed
  169. Farber HW, Barnett HF. Differences in prostaglandin metabolism in cultured aortic and pulmonary arterial endothelial cells exposed to acute and chronic hypoxia. Circ Res. 1991 May; 68(5):1446-57. PMID: 1902149.
    View in: PubMed
  170. Zimmerman LH, Levine RA, Farber HW. Hypoxia induces a specific set of stress proteins in cultured endothelial cells. J Clin Invest. 1991 Mar; 87(3):908-14. PMID: 1999500.
    View in: PubMed
  171. Farber HW. Differences in pulmonary and systemic arterial endothelial cell adaptation to chronic hypoxia. In Response and Adaptation to Hypoxia - Organ to Organelle (Lahiri S, Cherniak NS, Fitzgerald RS, eds). Oxford University Press. New York. 1991; 195-201.
  172. Saitz R, Williams BW, Farber HW. Atenolol-induced cardiovascular collapse treated with hemodialysis. Crit Care Med. 1991 Jan; 19(1):116-8. PMID: 1986875.
    View in: PubMed
  173. Farber HW, Rounds S. Effect of long-term hypoxia on cultured aortic and pulmonary arterial endothelial cells. Exp Cell Res. 1990 Nov; 191(1):27-36. PMID: 2226649.
    View in: PubMed
  174. Farber HW, Center DM, Rounds S, Danilov SM. Components of the angiotensin system cause release of a neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur Heart J. 1990 Apr; 11 Suppl B:100-7. PMID: 2194806.
    View in: PubMed
  175. Farber HW, Fairman RP, Rounds S, Millan JE, Glauser FL. Pulmonary hypertensive response to foreign body microemboli. Prostaglandins Leukot Essent Fatty Acids. 1990 Feb; 39(2):151-7. PMID: 2111555.
    View in: PubMed
  176. Farber HW, Marks EJ. Case records of the Massachusetts General Hospital (Case 1-1990). N Engl J Med. 1990; 322:43-52.
  177. Lamon-Fava S, McNamara JR, Farber HW, Hill NS, Schaefer EJ. Acute changes in lipid, lipoprotein, apolipoprotein, and low-density lipoprotein particle size after an endurance triathlon. Metabolism. 1989 Sep; 38(9):921-5. PMID: 2505019.
    View in: PubMed
  178. Farber HW, Fairman RP, Millan JE, Rounds S, Glauser FL. Pulmonary response to foreign body microemboli in dogs: release of neutrophil chemoattractant activity by vascular endothelial cells. Am J Respir Cell Mol Biol. 1989 Jul; 1(1):27-35. PMID: 2624757.
    View in: PubMed
  179. Benditt JO, Farber HW, Wright J, Karnad AB. Pulmonary hemorrhage with diffuse alveolar infiltrates in men with high-volume choriocarcinoma. Ann Intern Med. 1988 Oct 15; 109(8):674-5. PMID: 2458694.
    View in: PubMed
  180. Rounds S, Farber HW, Render ML, Barnard FA. Effects of hypoxia and hypercarbia on cultured endothelial cells. Chest. 1988 Mar; 93(3 Suppl):156S-157S. PMID: 3342697.
    View in: PubMed
  181. Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM, Kunches LM, Farber HW, Wedel SA, McCabe WR. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987 Nov 26; 317(22):1376-82. PMID: 2891032.
    View in: PubMed
  182. Farber HW, Center DM, Rounds S. Effect of ambient oxygen on cultured endothelial cells from different vascular beds. Am J Physiol. 1987 Oct; 253(4 Pt 2):H878-83. PMID: 3661737.
    View in: PubMed
  183. Farber HW, Laguarda R. Human pulmonary dirofilarial infection. Ann Intern Med. 1987 May; 106(5):777-8. PMID: 3565986.
    View in: PubMed
  184. Farber HW, Arbetter J, Schaefer EJ, Hill SP, Dallal G, Grimaldi R, Hill NS. Acute metabolic effects of an endurance triathlon. Ann Sports Med. 1987; 3:131-138.
  185. Villanueva AG, Farber HW. Pulmonary complications in AIDS patients. Curr Rev Respir Crit Care. 1987; 9:127-132.
  186. Farber HW, Weller PF, Rounds S, Beer DJ, Center DM. Generation of, lipid neutrophil chemoattractant activity by histamine-stimulated cultured endothelial cells. J Immunol. 1986 Nov 1; 137(9):2918-24. PMID: 3760577.
    View in: PubMed
  187. Farber HW. Long-term oxygen therapy in COPD. Am Rev Respir Dis. 1986 Jan; 133(1):173. PMID: 3942372.
    View in: PubMed
  188. Farber HW, Center DM, Rounds S. Bovine and human endothelial cell production of neutrophil chemoattractant activity in response to components of the angiotensin system. Circ Res. 1985 Dec; 57(6):898-902. PMID: 3905045.
    View in: PubMed
  189. Rounds S, Farber HW, Hill NS, O'Brien RF. Effects of endothelial cell injury on pulmonary vascular reactivity. Chest. 1985 Oct; 88(4 Suppl):213S-216S. PMID: 3930163.
    View in: PubMed
  190. Farber HW, Make B. Physiologic closure of a symptomatic patent foramen ovale with oxygen therapy. Am Rev Respir Dis. 1985 Jan; 131(1):181-3. PMID: 3966707.
    View in: PubMed
  191. Farber HW, Karlinsky JB, Faling LJ. Fatal outcome following nifedipine for pulmonary hypertension. Chest. 1983 Apr; 83(4):708-9. PMID: 6831965.
    View in: PubMed
  192. Farber H, Glauser FL. The effect of oral hydralazine on the pulmonary hemodynamics of patients with pulmonary foreign body granulomatosis. Chest. 1982 Dec; 82(6):708-12. PMID: 7140398.
    View in: PubMed
  193. Farber HW, Fairman RP, Glauser FL. Talc granulomatosis: laboratory findings similar to sarcoidosis. Am Rev Respir Dis. 1982 Feb; 125(2):258-61. PMID: 6278999.
    View in: PubMed
  194. Farber HW, Falls R, Glauser FL. Transient pulmonary hypertension from the intravenous injection of crushed, suspended pentazocine tablets. Chest. 1981 Aug; 80(2):178-82. PMID: 7249763.
    View in: PubMed
  195. Farber HA, Tucker HS, Jasnosz KM. Morbidity and mortality conference: thrombotic thrombocytopenic purpura. Va Med. 1981 Jun; 108(6):405-9. PMID: 7195635.
    View in: PubMed
  196. Farber HW, Kerkering TM, Jasnosz KM. Morbidity and mortality conference: acute pulmonary blastomycosis. Va Med. 1981 Mar; 108(3):177-82. PMID: 7223000.
    View in: PubMed
  197. Farber HW, Mathers JA, Glauser FL. Gallium scans and serum angiotensin converting enzyme levels in talc granulomatosis and lymphocytic interstitial pneumonitis. South Med J. 1980 Dec; 73(12):1663-7. PMID: 6255609.
    View in: PubMed
Harrison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department